MATRIX METALLOPROTEINASE-2 IN BONE MARROW OF PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MYELODISPLASTIC SYNDROME

DOI: https://doi.org/None

Lesnichenko I.F., Gritsaev S.V., Kostroma I.I., Chechetkin A.V.

Introduction. Search for correct markers for diagnosis, prognosis and evaluation of the effectiveness of chemotherapy is the most important problem of the modern oncohematology. The aim. To determine the clinical relevance of matrix metalloproteinase-2 (MMP-2) level in bone marrow plasma in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients. Methods. The MMP-2 level in bone marrow plasma was determined with immunoassay kits «Human MMP-2 immunoassay» (R&D Systems, USA). Results. There were no significant differences in the MMP-2 levels between MDS and active AML patients. At the same time MDS and AML patients without the complete remission had MMP-2 levels significantly lower than AML patients in the complete remission. There was observed the gain in MMP-2 levels after the successful therapy and decreasing of them after the beginning of the relapse. Conclusion. The level of MMP-2 in bone marrow plasma may be considered as promising index for the evaluation of the effectiveness of the therapy in AML and MDS patients. MMP-2 can be considered to participate in leukemogenesis.
Keywords: 
matrix metalloproteinase-2, acute myeloid leukemia, myelodysplastic syndrome
Список литературы: 
  1. Lesnichenko I.F., Gricaev S.V., Kapustin S.I. Matriksnye metalloproteinazy: harakteristika, rol` v leykozogeneze i prognosticheskoe znachenie. Vopr. Onkol. 2011; 57 (3): 286–94. [Lesnichenko I.F., Gritsaev S.V., Kapustin S.I. Matrix metalloproteinases: characterization, the role in the leukemogenesis and prognostic significance. Vopr. onkol. 2011; 57 (3): 286–94 (in Russian)]
  2. Chaundary A.K., Pandya S., Ghoh K., Nadkarni A. Matrix metalloproteinase and its drug targets therapy in solid and hematological malignancies: An overview. Mutat. Res. 2013; 1 (753): 7–23.
  3. Gialeli C., Theocharis A.D., Karamanos N.K. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J. 2011; 278 (1): 16–27.
  4. Klein T., Bischoff R. Physiology and pathophysiology of matrix metalloproteases. Amino Asids. 2011; 41 (2): 271–90.
  5. Yu X.F., Han Z.C. Matrix metalloproteinases in bone marrow: roles of gelatinases in physiological hematopoietic malignancies. Histol. Histopatol. 2006; 21 (5): 519–31.
  6. Lesnichenko I.F., Gricaev S.V., Sergeev A.N., Kostroma I.I. Aktivnost` matriksnyh metalloproteinaz MMP-2 i MMP-9 v plazme aspiratov kostnogo mozga bol`nyh ostrym mieloidnym leykozom. Biomed. Him. 2013; 59 (5): 578–84. [Lesnichenko I.F., Gritsaev S.V., Sergeev A.N., Kostroma I.I. Activity of matrix metalloproteinases MMP-2 and MMP-9 in aspirate’s plasma of bone marrow of patients with acute myeloid leukemia. Biomed. Khim. 2013; 59 (5): 578–84 (in Russian)]
  7. Vardiman J.W., Thiele J., Arber D.A., Brunning R.D., Borowitz M.J., Porwit A., Hamis N.L., Le Beau M.M., Hellstrom-Lindberg E., Tefferi A., Bloomfield C.D. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009; 114 (5): 937–51.
  8. Cheson B.D., Greenberg P.L., Bennett J.M., Lowenberg B., Wijermans P.W., Nimer S.D., Pinto A., Beran M., de Witte T.N., Stone R.M., Mittelman M., Sang G.F., Sore S.D., Schiffer C.A., Kantharjian H. Clinical application and proposal for modification of the International Working Group (WG) response criteria in myelodysplasia. Blood. 2006; 108 (2): 419–25.
  9. Cheson B.D., Bennett J.M., Kopecky K.J., Buchner T., Willman C.L., Estey E.N., Schiffer C.A., Doehner H., Tallman M.S., Lister T.A., Lo-Coco F., Willemze R., Biondi A., Hiddemann W., Larson R.A., Lowenberg B., Sanz M.A., Head D.R., Ohno R., Bloomfield C.D.; International working group for diagnosis, standartisation of response criteria, treatment outcomes and reporting standards for therapeutic trials in acute myeloid leukemia. J. Clin. Oncol. 2003; 21 (24): 4642–9.
  10. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., Vallespi T., Hamblin T., Oscier D., Ohyashiki K., Toyama K., Aul C., Muffi G., Bennett J. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 890 (6): 2079–88.
  11. Lesnichenko I.F., Gricaev S.V., Kostroma I.I. Matriksnye metalloproteinazy-2 i -9 v plazme aspiratov kostnogo mozga bol`nyh ostrym mieloidnym leykozom. Byul. SO RAMN. 2014; 6 (34): 13–6. [Lesnichenko I. F., Gritsaev S.V., Kostroma I.I. Matrix metalloproteinases-2 and -9 in plasma of bone marrow aspirates of patients with acute myeloid leukemia. Bjul. SO RAMN. 2014; 6 (34): 13–6 (in Russian)]
  12. Lesnichenko I.F., Gricaev S.V, Kostroma I.I. Znachenie opredeleniya matriksnyh metalloproteinaz MMP-2 i MMP-9 v plazme aspiratov kostnogo mozga bol`nyh ostrym mieloidnym leykozom. Vestnik Gematologii. 2015; XI (1): 47–52. [I.F Lesnichenko, S. V. Gritsaev, I. I. Kostroma. Significans of evaluation of matrixmetalloproteinases MMP-2 and MMP-9 in plasma of bone marrow aspirates of patients with acute myeloid leukemia. Vestnik Gematologii. 2015; XI (1): 47–52 (in Russian)]
  13. Aref S., Osman E., Mansy S., Omer N., Azmy E., Goda T., El-Sherbiny M. Prognostic relevance of circulating matrix metalloproteinase-2 in acute myeloid leukaemia patients. Hematol. Oncol. 2007; 25 (3): 121–6.
  14. Ries C., Loher F., Zang C, Ismair MG, Petrides PI. Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodisplastic syndromes. Clin. Cancer Res. 1999; 5 (1): 1115–24.